Trial reportDrug design, development and therapy2026
Oliceridine in the Prevention of Catheter-Related Bladder Discomfort: A Single-Center, Randomized, Double-Blind, Prospective Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate whether oliceridine is more effective than morphine in reducing the incidence of moderate-to-severe catheter-related bladder discomfort (CRBD) in male patients after transurethral surgery. Patients and Methods: This prospective, randomized, double-blind trial enrolled 372 adult male patients undergoing elective transurethral surgery with urinary catheterization. Patients were randomized to receive oliceridine (1 mg) or morphine (2 mg) intravenously 5 minutes before surgery end. CRBD incidence/severity, Numerical Rating Scale. (NRS), Postoperative nausea and vomiting (PONV), Aldrete recovery scores, adverse events, and the Quality of Recovery-15 scale (QoR-15) score were assessed. Results: The incidence and severity of CRBD at 3 hours postoperatively were significantly lower in the oliceridine group than in the control group (21.5% vs 72.1%; RR 0.298, 95% CI: 0.220-0.403; P<0.001). QoR-15 scores were higher in the oliceridine group on postoperative days 1-3 (P≤0.005). No serious adverse events occurred, and nausea/vomiting incidence and pain score showed no significant difference. Conclusion: Intraoperative oliceridine (1 mg) effectively reduces moderate-to-severe CRBD incidence and severity, improves early postoperative recovery quality, and is well-tolerated in male transurethral surgery patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.